- Home
- STAA vs BEAM Comparison
STAA vs BEAM Comparison
Compare STAA & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | STAA | BEAM |
|---|---|---|
| Founded | 1982 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Ophthalmic Goods | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 3.0B |
| IPO Year | 1995 | 2019 |
Fundamental Metrics
Financial Performance| Metric | STAA | BEAM |
|---|---|---|
| Price | $28.39 | $31.09 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 9 | 12 |
| Target Price | $22.81 | ★ $50.75 |
| AVG Volume (30 Days) | 721.6K | ★ 1.8M |
| Earning Date | 05-12-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 82.31 |
| EPS | ★ 0.10 | N/A |
| Revenue | ★ $239,442,000.00 | $24,000.00 |
| Revenue This Year | $30.82 | N/A |
| Revenue Next Year | $8.41 | $33.77 |
| P/E Ratio | $283.70 | ★ N/A |
| Revenue Growth | N/A | ★ 33.33 |
| 52 Week Low | $15.59 | $15.60 |
| 52 Week High | $35.87 | $36.44 |
Technical Indicators
Market Signals| Indicator | STAA | BEAM |
|---|---|---|
| Relative Strength Index (RSI) | 45.48 | 53.61 |
| Support Level | $28.03 | $26.96 |
| Resistance Level | $31.05 | $33.32 |
| Average True Range (ATR) | 1.22 | 2.16 |
| MACD | -0.45 | -0.09 |
| Stochastic Oscillator | 6.57 | 48.78 |
Price Performance
Historical ComparisonAbout STAA STAAR Surgical Company
Staar Surgical Co is a manufacturer of lenses. It designs, develops, manufactures, and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. The company offers two types of products: Implantable Collamer lenses (ICL), which are used in refractive surgery. The company generates almost all of its revenue from the sale of its ICL products. Geographically, the company generates key revenue from Foreign sales.
About BEAM Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.